alpha-fluoro-beta-alanine has been researched along with capecitabine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL | 1 |
| Bridgewater, J; Grange, S; Kimura, M; Kuranami, M; Lucraft, H; McAleer, J; Monkhouse, J; Poole, C; Reigner, B; Saeki, T; Sasaki, Y; Schüller, J; Watanabe, T; Weidekamm, E; Yorulmaz, C | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Cottica, D; Grignani, E; Locatelli, CA; Lonati, D; Negri, S; Pastoris, O; Santorelli, D; Sottani, C; Studioso, E; Zaratin, L | 1 |
| Beijnen, JH; Dorlo, TPC; Huitema, ADR; Jacobs, BAW; Kurk, SA; May, AM; Molenaar-Kuijsten, L; Steeghs, N | 1 |
| Beijnen, JH; Cats, A; de Vries, N; Guchelaar, HJ; Knikman, JE; Rosing, H | 1 |
2 trial(s) available for alpha-fluoro-beta-alanine and capecitabine
| Article | Year |
|---|---|
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta-Alanine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2003 |
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; beta-Alanine; Biotransformation; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Half-Life; Humans; Japan; Metabolic Clearance Rate; Middle Aged; Tissue Distribution; White People | 2003 |
4 other study(ies) available for alpha-fluoro-beta-alanine and capecitabine
| Article | Year |
|---|---|
Development of a sensitive and selective LC-MS/MS method for the determination of alpha-fluoro-beta-alanine, 5-fluorouracil and capecitabine in human plasma.
Topics: Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Dansyl Compounds; Deoxycytidine; Fluorouracil; Humans; Indicators and Reagents; Mass Spectrometry; Methyl Ethers; Quality Control; Reference Standards; Reproducibility of Results; Specimen Handling | 2009 |
A new, sensitive and versatile assay for quantitative determination of α-fluoro-β-alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC-MS/MS) system.
Topics: Antineoplastic Agents; beta-Alanine; Biotransformation; Calibration; Capecitabine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Fluorouracil; Health Personnel; Humans; Occupational Exposure; Occupational Health; Reference Standards; Reproducibility of Results; Risk Assessment; Tandem Mass Spectrometry; Urinalysis | 2018 |
Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta-Alanine; Capecitabine; Female; Fluorouracil; Humans; Male; Middle Aged; Muscle, Skeletal; Neoplasms; Prodrugs; Sex Factors; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Topics: beta-Alanine; Capecitabine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Fluorouracil; Humans; Lithium; Prodrugs; Tandem Mass Spectrometry | 2023 |